Navigation Links
FDA Announces Change of Location Notice for Upcoming Advisory,Committee Meeting

ROCKVILLE, Md., April 18, 2007--Due to water damage caused by flooding over the weekend, FDA has been forced to change the location for the upcoming Antiviral Drugs Advisory Committee meeting on April 24, 2007 to discuss new drug application for maraviroc 300 milligram tablets. Originally scheduled to be held at the FDA, Center for Drug Evaluation and Research Advisory Committee Conference Room, Room, 5630 Fishers Lane, in Rockville, MD, the meeting has been relocated to

Crown Plaza Hotel Silver Spring Kennedy Ballroom 8777 Georgia Avenue, Silver Spring, MD 20910.

If you need to arrange accommodations or get directions, you can contact the hotel directly at 301-589-0800. A map and local area information is available at the Silver Spring Downtown <http://www.silverspringdowntown.com/spring.php?pid=345> web site.

The committee will discuss new drug application (NDA) 022-128, maraviroc 300 milligram tablets, Pfizer, Inc., proposed for the treatment of antiretroviral-experienced patients with chemokine (c-c motif) receptor 5 (CCR5)--tropic human immunodeficiency virus (HIV).

Background material for this meeting will be available to the public no later than 1 business day before the meeting. Posted background material is available at http://www.fda.gov/ohrms/dockets/ac/cder07.htm#AntiviralDrugs <http://www.fda.gov/ohrms/dockets/ac/cder07.htm> . The Change in Meeting Location notice, and Federal Register Notice announcing the change will also be posted at this site.

The meeting is open to the public. There is no registration required, and no fees associated with attending FDA advisory committee meetings. However, please be sure to have a photo ID to enter this government building.

Contact Person: Cicely Reese, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: cicely.reese@fda.hhs.gov cicely.reese@fda.hhs.gov>

Please call the FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512531 for further, up-to-date information about this meeting.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Cicely Reese 7 days in advance of the meeting.

Richard Klein Office of Special Health Issues Food and Drug Administration

Kimberly Struble Division of Antiviral Products Food and Drug Administration

An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html

1-888-INFO-FDA (1-888-463-6332) -- main FDA Phone Number (for general inquiries)


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)...  Eli Lilly and Company (NYSE: ... to more efficiently focus resources on developing new ... workforce reductions, including those from a U.S. voluntary ... 3,500 positions. With the streamlining ... approximately $500 million that will begin to be ...
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... Conference at the Grand Hyatt hotel in New York.  ... at 11:40 a.m. Eastern Time. A live ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... The Davidson Institute for Talent Development will ... 27 at a reception in Washington D.C. The recipients received $50,000, $25,000 and ... “I am honored to be a Davidson Fellow Laureate,” said Rishab Gargeya, a ...
(Date:9/19/2017)... Brook, IL (PRWEB) , ... September 19, 2017 ... ... are significantly and positively linked to the Certified Emergency Nurse (CEN®) certification ... for Emergency Nursing (BCEN). The value of certification study, conducted by the Human ...
(Date:9/18/2017)... (PRWEB) , ... September 19, 2017 , ... ... Asia Pacific’s protein ingredient market , expected to grow at the fastest CAGR ... Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in Asia’ – ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... the finance role on the executive team adding a Chief Financial Officer following ... independent company. This expansion will support the strategic growth strategy Aegis has defined ...
(Date:9/18/2017)... Fort Lee, NJ (PRWEB) , ... September 18, 2017 , ... ... state’s history, CareOne, a New jersey based company, has launched an aid effort focused ... Irma as it battered the state over two days and left thousands homeless and ...
Breaking Medicine News(10 mins):